

## New financial goals for Surgical Science

**The Board of Surgical Science has decided on new financial goals for the company.**

*New financial goals:*

The goal is for Surgical Sciences' turnover in 2026 to amount to SEK 1,500 million. Achieving this target may entail supplementary acquisitions. The Educational Products business area is expected to grow by an average 10-15 percent annually over the period. With a larger and broader product portfolio, the products will have different growth rates. For example, Surgical Science has certain niche products to be able to submit complete tenders, but they are sold individually to a lesser extent. The Industry/OEM business area is expected to have increasing growth during the period as robotic surgery products containing technology from Surgical Science are launched on the market. During the period, other application areas are also anticipated to be digitalized, which together with expanded areas using simulation leads to increasing revenues.

Adjusted EBIT shall amount to 40 percent at the end of the period. Adjusted EBIT will be calculated as EBIT excluding amortization and write-downs of surplus values related to acquisitions.

In connection with the acquisition of Symbionix being announced on July 28, 2021, it was announced that Surgical Sciences' financial goals would be revised and communicated when the process of integrating the company had begun and the review had been completed. In the quarterly report for the third quarter, it was announced that Surgical Sciences' new financial targets would be announced prior to the publication of the year-end report in February.

*Surgical Science previously had the following financial goals, which were communicated in November 2019:*

The goal is for Surgical Sciences' turnover in 2024 to amount to SEK 400 million. Achieving this target may entail supplementary acquisitions. The Educational Products business area is expected to grow by an average 15 percent annually over the period. The Industry/OEM business area is expected to grow more unevenly depending on when new assignments are received and license payments commence. The target also presupposes that customers in the area release their products (mainly surgical robots but also other complicated medical device products) to the market and start generating sales.

EBITDA shall amount to at least 40 percent. During individual quarters, the margin may fluctuate, as a consequence of the sales mix and costs in order to enhance the organization's capacity to achieve the sales target.

Gothenburg, Sweden, January 25, 2022  
Surgical Science Sweden AB (publ)

**The press release, in its entirety, is available through the attachment or via:**

<https://surgicalscience.com/aktien/pressmeddelanden/>

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

**For further information, please contact:**

---

Gisli Hennermark, CEO

Telephone: +46-70-420 83 00

E-mail: [gisli.hennermark@surgicalscience.com](mailto:gisli.hennermark@surgicalscience.com)

Anna Ahlberg, CFO

Telephone: +46-70-855 38 35

E-mail: [anna.ahlberg@surgicalscience.com](mailto:anna.ahlberg@surgicalscience.com)

## **About Surgical Science Sweden AB (publ)**

---

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science has more than 200 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)).

*This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-01-25 08:30 CET.*

## **Attachments**

---

[New financial goals for Surgical Science](#)